Bryant Bianca M, Eaton Ellen, Li Li
Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, United States.
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Front Psychiatry. 2021 Aug 11;12:708283. doi: 10.3389/fpsyt.2021.708283. eCollection 2021.
The objective of this systematic review is to examine the relationship between opioid use disorder (OUD) and its related biomarkers, as well as the effects of pharmacotherapy for OUD on biomarkers. The eligibility criteria are the inclusion of human population studies focusing on biomarkers, including the immune system, related to OUD or opioid-related disorders. English, peer reviewed, original research, case studies or case series, and clinical trials were included in this review. Papers were excluded if they met one or more of the following criteria: animal studies, review articles, studies focusing only on OUD or opioid-related disorders without mention of potential biomarkers, studies focusing only on biomarkers and/or the immune system without relating to OUD or opioid-related disorders, and studies that focused on other substance use disorders other than OUD specifically. A PubMed, PsycINFO, and Cochrane databases search on August 25, 2020, yielded 101 results; only 14 articles met inclusion criteria that were included in this review. However, heterogeneity of study definitions and measurements should be noted. Various potential biomarkers indicated systemic, peripheral, and chronic inflammation in patients with OUD or opioid-related disorders. Medications, including buprenorphine and methadone, significantly decreased chronic inflammation in this population. Our results suggest that patients with OUD or opioid-related disorders have potential biomarkers that can be targeted to provide optimal treatment options for this population. A better understanding of potential biomarkers may assist to identify at-risk populations, monitor disease progression and treatment response, and develop therapeutic strategies for OUD. This review has been registered in PROSPERO (CRD42020202014).
本系统评价的目的是研究阿片类物质使用障碍（OUD）与其相关生物标志物之间的关系，以及OUD药物治疗对生物标志物的影响。纳入标准为纳入关注与OUD或阿片类物质相关疾病有关的生物标志物（包括免疫系统）的人群研究。本评价纳入英文、同行评审的原创研究、病例研究或病例系列以及临床试验。若论文符合以下一项或多项标准则被排除：动物研究、综述文章、仅关注OUD或阿片类物质相关疾病而未提及潜在生物标志物的研究、仅关注生物标志物和/或免疫系统而与OUD或阿片类物质相关疾病无关的研究，以及专门关注除OUD以外的其他物质使用障碍的研究。2020年8月25日在PubMed、PsycINFO和Cochrane数据库进行检索，得到101条结果；只有14篇文章符合纳入标准并被纳入本评价。然而，应注意研究定义和测量方法的异质性。各种潜在生物标志物表明OUD或阿片类物质相关疾病患者存在全身、外周和慢性炎症。包括丁丙诺啡和美沙酮在内的药物显著降低了该人群的慢性炎症。我们的结果表明，OUD或阿片类物质相关疾病患者具有潜在生物标志物，可作为靶点为该人群提供最佳治疗方案。更好地了解潜在生物标志物可能有助于识别高危人群、监测疾病进展和治疗反应，并制定OUD的治疗策略。本评价已在国际前瞻性系统评价注册库（PROSPERO，注册号：CRD42020202014）注册。
